Targeted biopsy
as diagnostic tool

As for any degenerative disease, early diagnosis in prostate cancer is crucial to improve patients’ quality of life and reduce the mortality rate, which amounts to 350,000 deaths each year.

When prostate cancer is suspected, diagnosis must be confirmed by a biopsy and subsequent histological analysis. However, biopsy is far from being accurate, as its mostly manual nature causes a significant diagnostic error that may exceed 25%.



More precision, safety, repeatability,
and control thanks to the AI.



Easy design that shortens the procedure
learning curve of the medical personnel.



Target identification and positioning
error drastically lowered.

Prostate cancer is the second most common cancer in men.

world icon


new cases


A paradigm shift in biopsy procedures


A single cart holding the robotic needle positioner and housing all the electronic components

The Robiopsy Project aims at evolving the robotic device for prostate cancer biopsy demonstrated during the ERC-PoC PROST into a product prototype that will be ready for clinical trials.

A multi-centric study will collect data for automatic prostate segmentation and lesion identification.

In parallel to the technical development, the project will analyse the business case of prostate biopsy in selected European Countries, and the time/cost reduction due to the new device.


The company was founded by a group of researchers from
the University of Verona, leaded by Professor Paolo Fiorini and with an experience in the field of medical robotics of more than 15 years.

Logo UNI Verona
Logo Needleye
Logo Universitat
Logo Dayone